The bottom line is if DCVax-L or D is proved to be better than any existing treatment in any indication in terms of safety and efficacy, it will be approved by FDA; even if L or D might be shown similar in efficacy and/or even safety to that of any existing treatment, it will still be approved by FDA as an alternative which can applied for specific patient populations.
While one may get carried away from a useless debate, he or she must always remember that at $0.5 a piece per share, basically the market has priced the company a failed company, the L trial a failed trial, LP a failed ceo, and all long investors failed hairballs, and nothing less.
Don't tell me the company will go bankrupt if you are genuine and have a bit biotech experience, only if LP had nefarious motive if you believe. A company like nwbo will not go bankrupt at foreseeable future, though it is a likelihood that the company will survive simply by diluting its existing share holders.
Nonetheless, as long as the potentials of D still exist, as long as there is still likelihood that L may still be used in combinations with other agents such as CIs even if L is proven a failure in brain cancer indication, a market cap of around $100 million will be normal, which will give you roughly $1 per share of stock price.
Not saying the company has not filed a BLA (rolling application or not), not saying the company has not sought AA, but what I am saying is the current situation indicated by share price has totally denied any possibility of those and regarded the company a failed company with a failed L trial.
It is then a natural, logic, reasonable and certain conclusion as long as investment is concerned: buy nwbo shares as many as and as much as one can afford at this option price.
It is either $0.5 loss or $30 gain or $300 gain.
Yes, good move re nwbo. On the other hand, people still don't understand it is still overly expansive of juno even with 30% haircut because the very concept of this class of treatment called cart-t is dead, not just this underlining p2 trial.
Move your money to nwbo the only player left in town -- cancer hypnotherapy before stupid hedges do the same!
It has been long written on the wall but today's reveling is the last call for people to wake up to the fact. Don't look at Wall Street's (particularly the street AF's) endless bashing on nwbo. Please to have an in-depth DD on nwbo, and you will love it.
The most wonderful thing is now you can pay option prices for nwbo shares thanks to endless, scandalous and orchestrated attacks on the company.
NWBO is the future of cancer hypnotherapy!
You sound like Pyrr, and Jerry hanging on stock MB without a penny stake. At least Jerry can read some SEC filing and have particularly interests in the usual warning sections.
I agreed. He is not only too old to have a correct vision, but may have bailed out some of his shares as he suddenly stopped enforcing his usual buy rating. What a pity!
I bet some "longs" will sell their shares today for a few pennies, which is good thing as those shares will be held my someones more determined and stable.
As you said, it is either zero (impossible) or $30 (easy to get there as long as the trial is a success).
Understandable, people will continually trading during this journey!
I fully share your sentiment, but on the other hand, it also creates opportunities as long as one believes his own long investment thesis. GL!
I think I should bump this up seeing those useless and distraction shorts taking the space endlessly. I again bought additional 1.3k today.
Some distractors constantly talked about the how the recent new release is to cover the nonappliance Nadqaq issue while continually forgetting to talked the essence:
1) There will be three multinational large three combination p2 trials with major immunotharaputic companies for three types of cancers in the near future, which may serve as pivotal trials for approvals;
2) DCvax-L partial halt for addtional patient screening may be resolved soon, and the trial is ongign so is dialog between the company and regulatory bodies;
3) The Nasdaq nonappliance should be resolved very quickly.
Too many positive things are going on, which are just got intentionally ignored by shorts.
Thank you Dan88 for making my finger on the keyboard today to buy those shares seem nobody wanted! GL to you and all longs.
I think you finally get some thing right even in speculation, so I give you a thumb up!
If you don't have experience in this aspect, one way for you to do is go search on any big league company to see how many security non-appliance you can dug out, you will be surprised. At end, they all gains appliance.
This is a good start for the company, thought not from LP or the board but from NASDAQ, which means those insurances identified in question have to be corrected, and any future issuance in the regulated scale has to be approved by shareholders.
It is a negative event turn-out-to-be positive event news dear. Hey how about those three big combo trials with three different sets of big league companies. Don't you see any positive about D now?
Oh well, how about the L-trial? It seems the issue will be resolved and since it is well over 300. To gain full enrollment seems just a month or two tasks after the issue is resolved. After that, the data will be know very quickly.